Stroke Research

At UI Health, our stroke experts are committed to always providing the highest level of stroke care 24/7. Our stroke doctors are at the forefront of stroke research, developing new technologies and therapies for treating stroke and identifying stroke risk. The earlier we can identify the risk of stroke, the better we can treat it.

Captiva

This study is relevant to public health because narrowing of brain arteries is one of the most common causes of stroke worldwide. Compelling evidence suggests novel antithrombotic medications could reduce the rate of stroke in patients with narrowed brain arteries. The proposed study will directly compare novel antithrombotic medications to standard care antiplatelet medications for preventing stroke and death from vascular causes in patients with narrowed brain arteries. The main intent of CAPTIVA is to establish that at least one of the three most popularly used, novel therapies being evaluated is more effective than the current standard. Those medications- along with preventative measures for other external, medical contributions for patients with high-stroke risk — will provide important safety and efficacy data on the three tested therapies and most important factors to control for universal prevention.

UI Health neurosurgeon Dr. Ali Alaraj is the lead investigator of this study.


Sleep Smart

There are certain aspects of your sleep that could get in the way of your recovery from a stroke and might contribute to another stroke. UI Health researchers are conducting a study to determine whether it is better to treat or not treat a condition called obstructive sleep apnea after someone has a stroke or TIA. The intention is to determine whether using CPAP – hopefully every night -- improves your recovery from stroke or keeps you from having another stroke in the future.

UI Health neurologist Dr. Gabriela Trifan is the principal investigator of this study.


Oceanic

The OCEANIC clinical trial program is designed to evaluate the use of Asundexian, as an oral FXIa inhibitor, in patients with atrial fibrillation (AF) at risk of stroke and in patients following acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA), aiming to improve the benefit-risk profile when compared to standard of care. The main purpose of this study is to learn whether Asundexian works better than placebo at reducing ischemic strokes in participants who recently had a non-cardioembolic ischemic stroke or TIA/mini-stroke when given in addition to standard antiplatelet therapy.

UI Health neurologist Dr. Fernando Testai is the principal investigator for this study.


ROSE LAWN

Some patients after ICH recover nearly back to normal, while others are left devastated by the stroke. This may be true with the same size and location of hemorrhage. If we can identify the different proteins or biologic mechanisms that help people to recover, we may be able to apply it to all ICH patients to improve recovery. The Recovery and Outcomes from StrokELongitudinal Assessment With Neuroimaging (ROSE-LAWN) study is the first long-term follow-up study for patients with ICH that repeats the MRI used at baseline as well as performing a comprehensive examination in a time frame of years after the ICH. Our purpose is to identify what causes some patients to develop a progressive decline in their cognition or thinking.

UI Health neurologist Dr. Fernando Testai is the principal investigator for this study.